Fulda Simone, Debatin Klaus-Michael
University Children's Hospital, Ulm, Germany.
Cell Cycle. 2007 Apr 1;6(7):790-2. doi: 10.4161/cc.6.7.4084. Epub 2007 Apr 27.
Resistance of human cancers to current treatment regimens remains a challenge in oncology. Therefore, there has been much interest in identifying molecular pathways that are responsible for primary or acquired resistance of cancers. Hypoxia is a characteristic feature of most solid tumors and has been associated with poor treatment response. In response to hypoxia cancer cells undergo a variety of adoptive changes including activation of signaling pathways, which promote cancer cell survival and block cell death. Hypoxia inducible factor-1 (HIF-1) is the major transcription factor that mediates adaptation of cancer cells to the hypoxic environment. There is mounting evidence that Hif-1alpha, the oxygen sensitive subunit of HIF-1, provides protection against cell death and stimulates tumor growth by upregulating genes that are involved in cellular energy metabolism. Thus, Hif-1alpha and hypoxia-inducible genes represent attractive targets for the development of pharmacological inhibitors, which may offer new therapeutic options for a wide range of adult and also pediatric malignancies.
人类癌症对当前治疗方案的耐药性仍然是肿瘤学中的一项挑战。因此,人们对确定导致癌症原发性或获得性耐药的分子途径非常感兴趣。缺氧是大多数实体瘤的一个特征,并且与治疗反应不佳有关。作为对缺氧的反应,癌细胞会经历各种适应性变化,包括信号通路的激活,这会促进癌细胞存活并阻止细胞死亡。缺氧诱导因子-1(HIF-1)是介导癌细胞适应缺氧环境的主要转录因子。越来越多的证据表明,HIF-1的氧敏感亚基Hif-1α通过上调参与细胞能量代谢的基因来提供细胞死亡保护并刺激肿瘤生长。因此,Hif-1α和缺氧诱导基因是开发药理抑制剂的有吸引力的靶点,这可能为广泛的成人和儿童恶性肿瘤提供新的治疗选择。